surmount-1 trial tirzepatide obesity without diabetes SURMOUNT-4 results just published in @JAMA_current 🛑Stopping #tirzepatide leads to regain of the majority of the lost weight. Is this a surprising result ⁉️ No #Obesity is a chronic disease and requires Early‐Onset Obesity and Tirzepatide Treatment:
Description
You complete a short online intake about your health and goals

Injection site concerns by body area Different areas of the body present different challenges
Inject semaglutide under the skin, in the abdomen, thigh, or upper arm
The peace of mind is worth it

FDA approved Zepbound (weight loss) in November 2023, Mounjaro (diabetes) in May 2022
